The American Chamber of Commerce to the EU (AmCham EU) fully recognises the pressure on public authorities in the EU and around the world to ensure timely access to COVID-19 vaccines. A strong economic recovery – and the return to normal life – relies on global access to vaccinations in a timely manner. Striving for this shared goal, stakeholders from both the public and private sectors are collaborating intensely to resolve the rapidly-evolving situation around the supply of vaccines.
International cooperation critical to ensure global access to COVID-19 vaccines
The American Chamber of Commerce to the EU (AmCham EU) fully recognises the pressure on public authorities in the EU and around the world to ensure timely access to COVID-19 vaccines. A strong economic recovery – and the return to normal life – relies on global access to vaccinations in a timely manner. Striving for this shared goal, stakeholders from both the public and private sectors are collaborating intensely to resolve the rapidly-evolving situation around the supply of vaccines.
AmCham EU is concerned that recent moves on export controls will fall short of their intended objectives. These measures risk disturbing the tightly calibrated and highly integrated supply chains used for the manufacturing and distribution of vaccines to patients globally. This can cause a ripple effect. In addition, restricting exports may spark retaliation from international partners, leading to further interruptions and ultimately hindering supply.
Putting an end to the COVID-19 crisis will only be possible through global cooperation. We encourage the EU, its Member States and other governments to increase collaboration as well as intensify the ongoing dialogue and partnership with industry. This will be critical in ensuring global access to COVID-19 vaccines and in mitigating the impact of the pandemic on the well-being of citizens and our economies.
Related items
Position Paper
11 Nov 2025
Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations
The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.
:focal())
News
27 Oct 2025
Advancing EU health policy through competitiveness and innovation
On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda.
:focal())
News
9 Oct 2025
Advancing European healthcare in Strasbourg
From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation.
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.